By Fineline Cube 
Bristol-Myers Squibb Co. (BMS, NYSE: BMY) announced that the U.S. Food and Drug Administration (FDA) has accepted for review a supplemental New Drug Application (sNDA) for Camzyos (mavacamten) as a potential treatment for adolescents aged 12 to <18 years with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). The FDA granted Priority Review with a Prescription Drug User Fee Act (PDUFA) decision date of September 30, 2026.
Regulatory Milestone & Development Status
| Parameter | Detail |
|---|---|
| Company | Bristol-Myers Squibb Co. (NYSE: BMY) |
| Drug Candidate | Camzyos (mavacamten) – cardiac myosin inhibitor (CMI) |
| FDA Status | sNDA accepted with Priority Review |
| Indication | Symptomatic obstructive HCM in adolescents (12 to <18 years) |
| PDUFA Date | September 30, 2026 |
| Current Approval | Adults with NYHA class II-III oHCM |
| Potential Distinction | First CMI approved for adolescent oHCM |
Clinical Evidence – Phase 3 SCOUT-HCM Trial
| Endpoint | Result | Significance |
|---|---|---|
| Primary Endpoint | Met with statistical significance | Clinically meaningful reduction in Valsalva LVOT gradient |
| LVOT Gradient Reduction | Significant improvement vs. placebo at Week 28 | Primary measure of oHCM severity |
| Safety Profile | Similar to adult population | Consistent with known Camzyos safety |
| Cardiac Function | No patients experienced LVEF <50% | Critical safety parameter maintained |
| Study Population | Symptomatic adolescents with oHCM | Addresses significant unmet need |
The SCOUT-HCM trial demonstrated that Camzyos effectively reduces left ventricular outflow tract obstruction—the hallmark hemodynamic abnormality in oHCM—while maintaining cardiac systolic function in adolescent patients.
Drug Profile & Mechanism of Action
- Molecule: Mavacamten (Camzyos) – first-in-class cardiac myosin inhibitor
- Mechanism: Allosteric inhibition of cardiac myosin ATPase, reducing hypercontractility and LVOT obstruction
- Target Population: Adolescents with symptomatic oHCM who previously had limited pharmacological options
- Current Status: Already approved for adults with NYHA class II-III oHCM
- Therapeutic Rationale: Addresses root cause of oHCM rather than just symptom management
Market Context & Unmet Medical Need
| Aspect | Analysis |
|---|---|
| Adolescent oHCM Prevalence | Estimated 25,000-30,000 adolescents with oHCM in the US; many undiagnosed or undertreated |
| Current Treatment Gaps | Beta-blockers and calcium channel blockers provide limited efficacy; surgical options carry significant morbidity |
| Camzyos Adult Market | Generated $892 million in 2025; adolescent approval could expand addressable population by 15-20% |
| Competitive Landscape | Aficamten (Cytokinetics) in development but lags behind Camzyos in regulatory progress |
| Clinical Significance | First disease-modifying therapy specifically studied and potentially approved for adolescent oHCM |
Strategic Implications & Commercial Outlook
- Market Expansion: Adolescent indication extends Camzyos’ commercial lifecycle and addresses previously untreatable population
- Early Intervention Potential: Treating adolescents may prevent long-term complications and improve quality of life during critical developmental years
- Diagnostic Catalyst: Approval likely to drive increased screening and diagnosis rates in adolescent populations
- Pricing Strategy: Premium pricing supported by first-in-class status and significant clinical benefit
- Global Regulatory Pathway: FDA approval would facilitate submissions to EMA and other international regulators
The Priority Review designation reflects the FDA’s recognition of the significant unmet medical need in adolescent oHCM and the potential for Camzyos to provide meaningful clinical benefit in this vulnerable patient population.
Forward‑Looking Statements
This brief contains forward-looking statements regarding regulatory submissions, clinical trial results, and commercial expectations for Camzyos. Actual results may differ due to risks including regulatory decisions, clinical trial variability, and competitive dynamics.-Fineline Info & Tech